Pegaptanib

Pegaptanib sodium
Clinical data
Trade namesMacugen
AHFS/Drugs.comMonograph
MedlinePlusa607057
Routes of
administration		Intravitreal injection
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life10 days
Identifiers
  • RNA, ((2'-deoxy-2'-fluoro)C-Gm-Gm-A-A-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-Am-Gm-(2'-deoxy-2'-fluoro)U-Gm-Am-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'fluoro)U-Am-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)U-(2'deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Gm-(3'→3')-dT), 5'-ester with α,α'-[4,12-dioxo-6[[[5-(phosphoonoxy)pentyl]amino]carbonyl]-3,13-dioxa-5,11-diaza-1,15-pentadecanediyl]bis[ω-methoxypoly(oxy-1,2-ethanediyl)], sodium salt[1]
CAS Number
DrugBank
ChemSpider
  • none
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC294H342F13N107Na28O188P28[C2H4O](m+n) (m+n≈900)
Molar mass~50 kg/mol
  (verify)

Pegaptanib[2] sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD).[3] It was discovered by NeXstar Pharmaceuticals (which merged with Gilead Sciences in 1999) and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the United States. Gilead Sciences continues to receive royalties from the drugs licensing. [4] Outside the US pegaptanib is marketed by Pfizer. Approval was granted by the U.S. Food and Drug Administration (FDA) in December 2004.[5]

  1. ^ Drug Information: Pegaptanib Sodium Injection Archived 2013-12-14 at the Wayback Machine
  2. ^ "Pegaptanib". go.drugbank.com. Retrieved 2023-10-24.
  3. ^ "Macugen (pegaptanib)" (PDF). European Medicines Agency: 1–3. 2010. Retrieved 2013-12-08.
  4. ^ "Larry Gold and Craig Tuerk (NeXstar Pharmaceuticals, Boulder, USA)". European Patent Office. 2011-02-16. Retrieved 2013-12-08.
  5. ^ "Highlights of Prescribing Information (Macugen)". Food and Drug Administration: 3–12. July 2007.